Caesarea, Israel, May 27, 2016 — LabStyle Innovations Corp. (NASDAQ:DRIO), developer of the Dario™ Diabetes Management Tool, today announced that the Company’s Chief Financial Officer, Zvi Ben-David will present at the Marcum MicroCap Conference being held June 1-2 in New York, NY and the LD Micro Invitational, being held June 7-9 in Los Angeles, CA.
During his presentations, Mr. Ben-David will discuss recent corporate and operational milestones, including the U.S. FDA Clearance and commercial launch of the Company’s Dario™ Smart Diabetes Management Solution.
Details of the presentations are as follows:
Conference: 2016 Marcum MicroCap Conference
Date: Wednesday, June 1, 2016
Time: 10:30 a.m. EDT
Location: Grand Hyatt New York, Imperial Room
Conference: LD Micro Invitational
Date: Tuesday, June 7, 2016
Time: 3:00 p.m. PDT
Location: Luxe Sunset Bel Air, Track 4
Investors or analysts attending either conference who are interested in meeting with Mr. Ben-David may request a meeting via the respective conference’s portal or by contacting Joseph Green or Lee Roth at 646-536-7013 / 7012 or jgreen@theruthgroup.com / lroth@theruthgroup.com.
About LabStyle Innovations
LabStyle Innovations Corp. (NASDAQ:DRIO) creates innovative mobile and digital tools that empower and engage users to lead healthier lives. LabStyle’s “Real data. Real time. Real improvements.” approach and strategy is positioning the company as a major player in the mHealth industry; an industry currently worth $10B and expected to reach $31B by 2020 according to Research2Guidance. LabStyle’s flagship product, The Dario™ Smart Diabetes Management Solution, is a platform for diabetes management that combines an all-in-one blood glucose meter, native smart phone app (iOS & Android), website portal and a wide variety of treatment tools to support more proactive and better informed decisions by users living with diabetes, their doctors and healthcare systems.
Cautionary Note Regarding Forward-Looking Statements
This news release and the statements of representatives and partners of LabStyle Innovations Corp. (the “Company”) related thereto contain or may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Statements that are not statements of historical fact may be deemed to be forward-looking statements. Without limiting the generality of the foregoing, words such as “plan,” “project,” “potential,” “seek,” “may,” “will,” “expect,” “believe,” “anticipate,” “intend,” “could,” “estimate” or “continue” are intended to identify forward-looking statements. For example, the Company is using forward-looking statements in this press release when the Company discusses its opportunities in the mHealth industry and the expected size of the mHealth industry. Readers are cautioned that certain important factors may affect the Company’s actual results and could cause such results to differ materially from any forward-looking statements that may be made in this news release. Factors that may affect the Company’s results include, but are not limited to, regulatory approvals, product demand, market acceptance, impact of competitive products and prices, product development, commercialization or technological difficulties, the success or failure of negotiations and trade, legal, social and economic risks, and the risks associated with the adequacy of existing cash resources. Additional factors that could cause or contribute to differences between the Company’s actual results and forward-looking statements include, but are not limited to, those risks discussed in the Company’s filings with the U.S. Securities and Exchange Commission. Readers are cautioned that actual results (including, without limitation, the timing for and results of the Company’s commercial and regulatory plans for Dario™ as described herein) may differ significantly from those set forth in the forward-looking statements. The Company undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable law.
| Press | Investor Relations |
| Brenda Zeitlin
LabStyle Innovations Corp. |
Lee Roth
The Ruth Group |
| 1 800 896 9062 | 646-536-7012 |
| Brenda@mydario.com | lroth@theruthgroup.com |